Hope one of our fellow investors on this board won’t
Hope one of our fellow investors on this board won’t mind- but would love to share some the wise words he offered when I was early on in this process:
‘Lead with safety.’ ‘Given the Hellscape that is "cancer therapies" today, your best bet will be to hammer home, constantly, LLMab's *impeccable* safety profile.... Lack of SAEs, well tolerated, one thousand patients over five years, in a population as fragile as HIV patients... “It won't hurt and there's nothing to lose" is what needs to be understood.’
(And – my goodness- he is so right on multiple levels. Sick folks, at least the ones I have had THE conversations with, are compelled/driven/feel the need to give 100% trust to their doctors. They and their docs don’t want to risk adding ANY harm or – more discomfort.)
In the case of my friend’s doc- I also highlighted the fact that leronlimab does not replace their current treatment; as this was a huge mind block and an absolute deal breaker for my lovely friend and her doc.
He also tried to prepare me to be ignored or dismissed.
(Again- he is correct; has been a fight. . . . but now I know to expect it. Sounds like you are very aware and ready; much more than I was.)
(Please forgive me JLang- just too good to keep to myself.)
This entire ordeal has taught me to be open-minded/realistic (and out of the conspiracy camp- at least for this piece) to understand that clinical trials take time for the CytoDyn's of the world. So many human beings behind the 'updates' that are doing the best they can.
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
Top 5 Most Recently Viewed Articles
Great Hearts Launches New Support Services for Classical Schools Great Hearts, a leader in K-12 classical education, proudly announces the launch of Great Hearts Services. This new initiative aims to provide extensive instructional and operational support to classical schools throughout the country. The goal is not just to offer help but to partner with educational...
Continue Reading
Funding Announcement for Kindred In an exciting development, Kindred, a pioneering home swapping platform, has successfully raised $125 million to fuel its expansion. This substantial funding marks a significant step in establishing home swapping as a legitimate option in the travel industry, which has traditionally revolved around hotels and short-term rentals....
Continue Reading
Revolutionizing Emergency Response with Technology Motorola Solutions (NYSE: MSI) is making significant strides in public safety by integrating real-time 9-1-1 intelligence into law enforcement's crime response systems. By funneling critical 9-1-1 call data directly into real-time crime centers (RTCCs), Motorola Solutions ensures that police can respond faster and more...
Continue Reading
Introducing Story Camp™ by GhostRanch Communications GhostRanch Communications is excited to unveil Story Camp™, a retreat specifically designed for emerging leaders looking to enhance their presentation and storytelling skills. This inventive program aims to provide participants with the tools they need to elevate their communication and engage effectively with their...
Continue Reading
Leica Biosystems Sets Sights on StatLab There's a fresh chapter brewing in the niche of cancer diagnostics as Leica Biosystems, riding on the shoulders of Danaher, decides it's time to acquire StatLab. Consider this a big shake-up in the anatomic pathology playground. Leica is known for striding through the path of cancer diagnostics with aplomb, while StatLab brings to...
Continue Reading